Evidence map›Paper›PMID 39891488›Full record

ArticleAnnals of neurology2025

Accelerated Cellular Senescence in Progressive Multiple Sclerosis: A Histopathological Study.

Dimitrios Papadopoulos, Roberta Magliozzi, Sara Bandiera, Ilaria Cimignolo, Elena Barusolo, Lesley Probert, Vassilis Gorgoulis, Richard Reynolds, Richard Nicholas

Abstract read
In one paragraph

Article in Annals of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dimitrios PapadopoulosSchool of Medicine, European University, Nicosia, Cyprus.ORCID 0000-0003-1806-7740
Roberta MagliozziDepartment of Neurosciences and Biomedicine and Movement, The Multiple Sclerosis Center of University Hospital of Verona, Verona, Italy.ORCID 0000-0001-8284-7763
Sara BandieraDepartment of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
Ilaria CimignoloDepartment of Neurosciences and Biomedicine and Movement, The Multiple Sclerosis Center of University Hospital of Verona, Verona, Italy.
Elena BarusoloDepartment of Neurosciences and Biomedicine and Movement, The Multiple Sclerosis Center of University Hospital of Verona, Verona, Italy.
Lesley ProbertLaboratory of Molecular Genetics, Hellenic Pasteur Institute, Athens, Greece.
Vassilis GorgoulisMolecular Carcinogenesis Group, Department of Histology and Embryology, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Richard ReynoldsDepartment of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
Richard NicholasDepartment of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.ORCID 0000-0003-0414-1225

Funding

Multiple Sclerosis Society
6 · The paper itself

Abstract

objectiveThe neurodegenerative processes driving the build-up of disability in progressive multiple sclerosis (P-MS) have not been fully elucidated. Recent data link cellular senescence (CS) to neurodegeneration. We investigated for evidence of CS in P-MS and sought to determine its pattern.

methodsWe used 53BP1, p16, and lipofuscin as markers of CS in white matter lesions (WMLs), normal appearing white matter (NAWM), normal appearing cortical gray matter (NAGM), control white matter (CWM), and control gray matter (CGM) on autopsy material from patient with P-MS and healthy controls. Senescence-associated secretory phenotype (SASP) factors were quantified in cerebrospinal fluid (CSF).

resultsP16

interpretationOur data indicates that CS primarily affects actively demyelinating gray and WMLs. A higher senescent cell load in P-MS is associated with faster disability progression and death. ANN NEUROL 2025;97:1074-1087.

Indexed as

Cellular SenescenceMultiple Sclerosis, Chronic ProgressiveWhite MatterAdultAgedCyclin-Dependent Kinase Inhibitor p16FemaleGray MatterHumansLipofuscinMaleMiddle AgedCyclin-Dependent Kinase Inhibitor p16Lipofuscin

Identifiers

PMID39891488
PMCPMC12081997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.